Pharmaceutical Perspectives of Cancer Therapeutics: Current Therapeutic Uses of Monoclonal Antibodies

作者: Michael D. Axelson , David E. Gerber

DOI: 10.1007/978-1-4419-0131-6_11

关键词:

摘要:

参考文章(185)
R. Longo, G. Gasparini, Challenges for patient selection with VEGF inhibitors Cancer Chemotherapy and Pharmacology. ,vol. 60, pp. 151- 170 ,(2007) , 10.1007/S00280-006-0403-6
Deborah Schrag, The price tag on progress--chemotherapy for colorectal cancer. The New England Journal of Medicine. ,vol. 351, pp. 317- 319 ,(2004) , 10.1056/NEJMP048143
Cormac Sheridan, TeGenero fiasco prompts regulatory rethink Nature Biotechnology. ,vol. 24, pp. 475- 476 ,(2006) , 10.1038/NBT0506-475
Alejandro D Ricart, Anthony W Tolcher, Technology insight: cytotoxic drug immunoconjugates for cancer therapy. Nature Reviews Clinical Oncology. ,vol. 4, pp. 245- 255 ,(2007) , 10.1038/NCPONC0774
Russell J. Schilder, Greg Wiseman, Christine A. White, Leo I. Gordon, Arturo Molina, Thomas Witzig, Christos Emmanouilides, Andrew Raubtischek, Mohamed Darif, Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study Blood. ,vol. 103, pp. 4429- 4431 ,(2004) , 10.1182/BLOOD-2003-11-3883
Steven M Ewer, Michael S Ewer, Cardiotoxicity Profile of Trastuzumab Drug Safety. ,vol. 31, pp. 459- 467 ,(2008) , 10.2165/00002018-200831060-00002
William E. Carson, Robin Parihar, Matthew J. Lindemann, Nicola Personeni, Julie Dierksheide, Neal J. Meropol, Jose Baselga, Michael A. Caligiuri, Interleukin‐2 enhances the natural killer cell response to Herceptin‐coated Her2 / neu‐positive breast cancer cells European Journal of Immunology. ,vol. 31, pp. 3016- 3025 ,(2001) , 10.1002/1521-4141(2001010)31:10<3016::AID-IMMU3016>3.0.CO;2-J
Gregory P Adams, Louis M Weiner, Monoclonal antibody therapy of cancer Nature Biotechnology. ,vol. 23, pp. 1147- 1157 ,(2005) , 10.1038/NBT1137